Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 21 |
| Active Pipeline (Recruiting Now) | 1 (0) |
| Completed vs Stopped Early | 19 / 1 (4.8%) |
| Median Closed Actual Enrollment | 335 participants |
| Physical Hospital Site Disclosure | 98.2% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05028582 | Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) | Phase III | COMPLETED |
| NCT04973228 | Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) | Phase III | COMPLETED |
| NCT04286607 | Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | Phase III | COMPLETED |
| NCT04091646 | Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | Phase II | COMPLETED |
| NCT04445987 | Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Arcutis Biotherapeutics Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.